A new startup company commercialising an ultra-high throughput enzyme discovery and improvement technology

传统上，支撑制造业的化学物质是由有限的化石化学物质和过程驱动的，我们现在知道，这些化学物质和过程本质上是不可持续的，对人类和地球都有害。我们可以利用生物学的自然力量来建立一个更可持续的系统：一个循环的全球生物经济。酶是一种生物催化剂，可以促进和加速化学反应，但需要研发。我们新成立的公司将彻底改变酶的发现和改进，为制药、化学品、农用化学品、化妆品、调味品和生物燃料等市场提供生物经济难题的关键部分。我们的创新是一种同时实验测试数百万种酶的能力，比现有技术更快、更有效、更成功地找到最适合这项工作的酶。鉴于全球酶市场的价值估计已经达到115亿美元，这笔交易的回报可能是巨大的。据估计，当今全球经济中多达60%的物质投入可以通过生物手段生产或替代（生物经济）。我们将在生产过程中增加酶的采用，受益于以下可持续性优势（绿色化学）：*降低排放*减少加热和加压要求*减少废物/步骤/化学品使用*可再生原料*减少废水处理（可生物降解）我们在BBSRC创新到大学研究商业化（ICURe）计划的市场发现阶段确认了我们业务的卓越潜力。该项目将在诺丁汉启动一家新的英国生物技术公司，创造高科技就业机会，支持地区和国家供应链公司，最终将全球投资带到东米德兰兹郡，并从出口到全球市场中获得收入。

The chemistry that underpins manufacturing has traditionally been driven by finite fossil chemicals and processes that we now understand are inherently unsustainable and bad for both people and the planet. We can turn to the natural power of biology for a more sustainable system: a circular global bioeconomy. Enzymes are biological catalysts which enable and accelerate chemical reactions, but require R&D. Our new startup company will revolutionise enzyme discovery and improvement, enabling a key piece of the bioeconomy puzzle in markets such as pharmaceuticals, chemicals, agrichemicals, cosmetics, flavourings and biofuels. Our innovation is an ability to experimentally test many millions of enzymes simultaneously, to find the best one for the job more quickly, efficiently, and successfully than existing technologies. The prize could be enormous, with the global enzymes market already worth an estimated $11.5bn.It is estimated that as much as 60% of the physical inputs to the global economy today could be produced or substituted using biological means (the bioeconomy). We will increase the adoption of enzymes in manufacturing processes, benefiting from the following sustainability advantages (green chemistry):* Lower emissions* Reduced heating and pressurisation requirements* Reduced waste/steps/chemical usage* Renewable feedstocks* Reduced effluent treatment (biodegradable)We confirmed the excellent potential of our business during the market discovery phase of the BBSRC Innovation to Commercialisation of University Research (ICURe) programme. This project will kickstart a new UK biotech company based in Nottingham, creating high-tech jobs, supporting regional and national supply chain companies, eventually bringing global investment to the East Midlands and revenue from exports to global markets.